Longevity & aging
Extend healthspan. Aging is the single largest driver of disease burden, and it is treatable.
The scale of it
years (global life expectancy at birth)
The capital on it
Aging-biology research plus dedicated longevity biotech (Altos, Retro, NewLimit and peers, annualized). Excludes general pharma R&D on age-related diseases (~$300B/yr industry-wide).
source: NIA budget (~$4.4B) + longevity-biotech venture funding (Longevity.Technology tracking) · confidence low · estimate, improvable by PR
The prize at the limit
A company that meaningfully extends healthy human lifespan faces the highest willingness-to-pay in existence: people will spend everything for more healthy years. The prize is a sizable fraction of the entire pharmaceutical industry, redirected to the winner.
comparable: the combined market cap of big pharma · confidence low · a ceiling, not a forecast
The trade: demand is high, only $8B/yr of capital is flowing (0.04× its fair share), and the prize at the limit is $3T. This is a Request for Startups and a Request for Investors at once.
The summary lives here. The full whitepaper walks through the four-axis ranking, existing alternatives, proposed direction, cost & scale, and suggested investors — in the spirit of Hyperloop Alpha.
Severity · WTP / wealth
share of affected person’s wealth they would pay for a solution
Current solutions
quality of existing solutions — low score = high opportunity
Market size · TAM
USD / year the world is already paying
Time · OOM to impact
order-of-magnitude horizon to civilizational-scale impact
Capital · OOM to solve
cumulative R&D + deployment + supply chain across the arc
Priority score
12
importance × urgency, 0–100
Importance
25
humans affected × severity, gated by market
Urgency
47
direction of travel + solution gap
Neglectedness
6/10Aging biology is underfunded relative to disease-by-disease medicine, despite aging being the largest shared risk factor.
medTractability
4/10Promising biology (senolytics, partial reprogramming, aging clocks) but no approved intervention that slows aging in humans yet.
lowWays to help
Build longitudinal aging biomarkers or geroscience tools that make the field falsifiable.
Work on the biology of aging or the regulatory path to "aging as an indication".
Organizations
- Buck Instituteresearch
- Hevolution Foundationfunder
People to follow
- Cynthia Kenyonaging biologist, Calico
- Morgan Levineaging-clock researcher
Three-lens scoring
Aging underlies cardiovascular disease, cancer, neurodegeneration, and frailty. Every human alive is affected. The hallmarks-of-aging framework (López-Otín et al.) gives discrete targets: senescent cell clearance, epigenetic reprogramming, stem cell exhaustion. Partial cellular reprogramming (Altos, Retro, NewLimit) and geroprotective drugs (rapamycin, metformin class) are in early trials. Utility delta is enormous: current median healthspan ~75 years, theoretical ceiling unknown and likely much higher.
The success vision · 30 years horizon
If we solve this, here is the world we get.
Before · today
Healthspan declines starting ~age 50. Aging treated as inevitable rather than as a disease. ~100M humans living with frailty-driven decline.
After · 30 years
Healthspan extended by 20+ years. Aging recognized as a treatable condition with FDA-approved interventions. 100→120-year healthy lifespan common in cohorts born after 2030.
Voices on this quest
3 thinkersNeuralink targets brain and spinal-cord disease as near-term deliverables with long-term implications for human-AI symbiosis and healthspan.
Extending healthy human life is a core progress goal. Curing aging is as legitimate a target as curing any single disease.
Human lifespan extension is on the canonical list of "good quests that require massively leveled heroes."
Companies on this quest
8 mappedDe-extinction and genetic engineering. Biosecurity adjacency via rapid genome editing and cold-chain logistics.
Cellular rejuvenation via partial reprogramming. $3B at founding with Shinya Yamanaka on scientific board.
AI-driven drug discovery. Industrializes biology through automated phenotypic screening at scale.
Alphabet-spinoff applying AlphaFold-class ML to drug design. Deals with Novartis and Eli Lilly.
Alphabet company for aging biology. Research partnership with AbbVie; long-horizon mandate rare in pharma.
Cellular reprogramming, autophagy, and plasma-exchange therapeutics. Seed-funded by Sam Altman at $180M.
Partial reprogramming for aging, started by Blake Byers, Jacob Kimmel, and Brian Armstrong.
FDA-track longevity drug for dogs. First-of-its-kind lifespan-extension regulatory pathway.
Capital funding this quest
5 allocatorsEmergent Ventures
GrantFast grants. High-variance, unconventional, talent-first.
best for: Unproven people with a weird, specific idea and no credential path.
Thiel Fellowship
Fellowship$100k to stop out of school and build something important.
best for: Under-22 builders with spiky talent and a real project.
Deep Science Ventures
Venture StudioOutcome-first venture creation. Define the holy-grail outcome, then recruit founders.
best for: Founders who want a co-founder thesis and institutional support from day one.
Founders Fund
Venture CapitalContrarian hard tech that rebuilds the industrial base.
best for: Scaling massive hard-tech quests, space, defense, biotech, fusion.
Lux Capital
Venture CapitalCounter-conventional science at the edges of physics and biology.
best for: Technical founders at the frontier who need contrarian conviction capital.